Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$17.82 - $22.89 $17,820 - $22,890
1,000 Added 5.36%
19,640 $441,000
Q4 2022

Feb 07, 2023

BUY
$18.47 - $26.14 $344,280 - $487,249
18,640 New
18,640 $392,000
Q3 2021

Mar 09, 2022

SELL
$12.98 - $25.03 $798,270 - $1.54 Million
-61,500 Closed
0 $0
Q2 2021

Mar 09, 2022

BUY
$14.11 - $26.4 $867,765 - $1.62 Million
61,500 New
61,500 $897,000

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.36B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.